Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SOFIVA GENOMICS CoROCO:6615 +0.15%68 Days Payable is 26.04 as of Dec. 2025, which is 20% below its 10-year median of 32.75. GuruFocus rates ROCO:6615 with a GF Score™ of 68/100 and a GF Value™ of NT$30.94 (Fairly Valued). The stock has 3 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, SOFIVA GENOMICS Co ranks worse than 79.47% on this metric.
The historical rank and industry rank for SOFIVA GENOMICS Co's Days Payable or its related term are showing as below:
ROCO:6615'
s Days Payable Range Over the Past 10 Years
Min: 23.7 Med: 32.75 Max: 55.46
Current: 28.85
During the past 13 years, SOFIVA GENOMICS Co's highest Days Payable was 55.46. The lowest was 23.70. And the median was 32.75.
ROCO:6615's Days Payable is ranked worse than 79.47% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs ROCO:6615: 28.85
SOFIVA GENOMICS Co's Days Payable
declined
from Dec. 2024 (28.59) to Dec. 2025 (26.04).
It may suggest that SOFIVA GENOMICS Coaccelerated paying its suppliers.
SOFIVA GENOMICS Co Days Payable Related Terms
SOFIVA GENOMICS Co Days Payable Historical Data
* Premium members only.
The historical data trend for SOFIVA GENOMICS Co's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6615 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, SOFIVA GENOMICS Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SOFIVA GENOMICS Co Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, SOFIVA GENOMICS Co's Days Payable distribution charts can be found below:
* The bar in red indicates where SOFIVA GENOMICS Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
SOFIVA GENOMICS Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SOFIVA GENOMICS Co (ROCO:6615) has a Days Payable of 26.04 as of Dec. 2025. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SOFIVA GENOMICS Co and its competitors. This is 20% below median its historical median of 32.75. Over the past decade, SOFIVA GENOMICS Co's Days Payable has ranged from 23.70 to 55.46. According to the industry distribution chart, SOFIVA GENOMICS Co ranks #151 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 79.5%.
Is SOFIVA GENOMICS Co's Days Payable too high?
SOFIVA GENOMICS Co's current Days Payable of 26.04 is 20% below median its 10-year median of 32.75. Over the past 10 years, this metric has ranged from a low of 23.70 to a high of 55.46. The Medical Diagnostics & Research industry median Days Payable is 64.64. SOFIVA GENOMICS Co's value of 26.04 is 59.7% below this industry median. Based on the distribution chart, SOFIVA GENOMICS Co ranks #151 out of 190 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, SOFIVA GENOMICS Co has a GF Score™ of 68/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does SOFIVA GENOMICS Co's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, SOFIVA GENOMICS Co ranks #151 out of 190 companies for Days Payable. This places SOFIVA GENOMICS Co in the lower half of its industry. The industry median Days Payable is 64.64. SOFIVA GENOMICS Co's value of 26.04 is 59.7% below this benchmark. Historically, SOFIVA GENOMICS Co's own Days Payable has ranged from 23.70 to 55.46 over the past decade. While the company's 10-year median is 32.75 vs. the industry median of 64.64, SOFIVA GENOMICS Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SOFIVA GENOMICS Co's current Days Payable of 26.04 is 59.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on SOFIVA GENOMICS Co and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SOFIVA GENOMICS Co's current Days Payable is 26.04, which is 20% below median its own 10-year median of 32.75. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SOFIVA GENOMICS Co stock overvalued right now?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co (ROCO:6615) is currently considered Fairly Valued. The stock's GF Value™ is NT$30.94, compared to a current price of NT$34.05 — trading 10.1% above its estimated fair value. The current Days Payable is 26.04, which is 20% below median its 10-year median of 32.75 and 59.7% below the Medical Diagnostics & Research industry median of 64.64. SOFIVA GENOMICS Co's overall GF Score™ is 68/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For SOFIVA GENOMICS Co (ROCO:6615), the current Days Payable is 26.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SOFIVA GENOMICS Co (ROCO:6615) Overvalued in 2026?
Based on GuruFocus' analysis, SOFIVA GENOMICS Co stock appears to be overvalued.
The current stock price of NT$34.05 is trading 10.1% above its estimated GF Value™ of NT$30.94.
GuruFocus considers SOFIVA GENOMICS Co to be Fairly Valued.
Key valuation signals for ROCO:6615:
Days Payable: 26.04 (20% below median its 10-year median of 32.75)
GF Value™: NT$30.94 vs. price of NT$34.05 (10.1% above fair value)
Industry Position: 59.7% below the Medical Diagnostics & Research median (#151 of 190)
No single metric tells the full story. See the ROCO:6615 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SOFIVA GENOMICS Co Ltd provides medical diagnostic services. The services offered by the company include Prenatal, Reproductive, Cancer, Precision Medicine, Newborn, and Rare Diseases. Its testing categories include Genetic, Biochemical, and Chromosome. The business items of Sofiva Group are pre-pregnancy, prenatal, and neonatal genetic testing and medical testing, and other service income. Geographically, it generates the vast majority of its revenue from Taiwan.
68GF Score
Get the complete analysis for ROCO:6615
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6615 has been successfully added to your 
